STING mRNA therapy / Hanmi - LARVOL DELTA

Next-generation STING mRNA therapy with reduced toxicity and dual action against cancer by boosting immunity and inducing tumor cell death (AACR 2026) - "Our data show that an mRNA-encoded, ligand-independent STING analog overcomes these barriers, enabling transient systemic activation that translates into sustained anti-tumor immunity. These findings support further development of STING mRNA therapeutics as a next-generation immuno-oncology strategy."

IO biomarker • Tumor cell • Oncology • IFNB1 • STING